Reshape Lifesciences Inc.
Doing business as (A Development Stage Company) Reshape Lifesciences Inc.
- UEI
- YL7CYVSRUN55
- CAGE
- 61TK5
- Primary NAICS
- 813990 Other Similar Organizations (except Business, Professional, Labor, and Political Organizations)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- medtimo.com
- Founded
- 2025
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 59 Miscellaneous Retail
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Diabetic targeted dual neuromodulation parametric optimization - project summary/abstract 31 million americans suffer… | National Institute of Diabetes and Digestive and Kidney Diseases | $345,650 | |
| High-definition endoscopic ultrasound navigation for targeted dual neuromodulation therapy - project summary/abstract 31… | National Institute of Diabetes and Digestive and Kidney Diseases | $331,451 | |
| Hypoglycemia vagal nerve stimulation therapy (hvns therapy) - project summary/abstract 30.3 million americans are… | National Institute of Diabetes and Digestive and Kidney Diseases | $600,000 | |
| Diabetes block stimulation neuromodulation therapy | National Institute of Diabetes and Digestive and Kidney Diseases | $299,048 | |
| Implant | Veterans Integrated Service Network 17 | $17,000 |
About Reshape Lifesciences Inc.
Reshape Lifesciences Inc. is a corporate for-profit organization registered in SAM.gov since June 17, 2010, with active registration through August 1, 2025. Classified as a small business joint venture, the company appears to be focused on developing innovative medical technologies, specifically targeting diabetes-related treatments and neurological interventions. The organization is in a development stage, concentrating on research and development of advanced medical therapies that involve neurostimulation and targeted nerve modulation techniques.
The company has received multiple federal grant awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program. Their grant-funded research has consistently centered on developing novel therapeutic approaches for type 2 diabetes mellitus, with a specific focus on targeted dual neuromodulation (TDN) therapies. Specific research projects include developing implantable pulse generator systems that can block and stimulate specific branches of the vagus nerve to improve glycemic control, creating high-definition endoscopic ultrasound navigation techniques for precise nerve stimulation, and designing hypoglycemia vagal nerve stimulation (HVNS) systems to help manage blood glucose levels. These research efforts are conducted through Phase I Small Business Innovation Research (SBIR) grants, with each project aimed at demonstrating feasibility, minimizing off-target physiological effects, and developing potential commercial medical interventions for diabetes management.
Quick answers
What is Reshape Lifesciences Inc.'s UEI?
Reshape Lifesciences Inc.'s Unique Entity ID (UEI) in SAM.gov is YL7CYVSRUN55.
What is Reshape Lifesciences Inc.'s CAGE code?
Reshape Lifesciences Inc.'s CAGE code is 61TK5.
What is Reshape Lifesciences Inc.'s primary NAICS code?
Reshape Lifesciences Inc.'s primary NAICS code is 813990 (Other Similar Organizations (except Business, Professional, Labor, and Political Organizations)).
Is Reshape Lifesciences Inc. registered in SAM.gov?
Reshape Lifesciences Inc.'s SAM.gov registration expired on July 22, 2026.
What is Reshape Lifesciences Inc.'s most recent federal award?
Reshape Lifesciences Inc.'s most recent federal grant award is Diabetic targeted dual neuromodulation parametric optimization - project summary/abstract 31 million americans suffer… (R43DK137628), from National Institute of Diabetes and Digestive and Kidney Diseases, on August 20, 2024.
On GovTribe
See Reshape Lifesciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors